Developer docs
API playgroundTry for free, no card

Search company profiles

Medac Group

Full company profile

uuid002fk8u

Namestring
Medac Group
Legal namestring
medac Gesellschaft für klinische Spezialpräparate m.b.H.
Websiteurl
medac-group.com
Company typeenum
Private
Founded yearint
1970
Descriptiontext

medac Group is a privately-held German pharmaceutical company founded in 1970 and headquartered in Wedel, near Hamburg. The company develops, manufactures, and distributes specialty pharmaceutical products across four therapeutic areas: rheumatology, urology, hematology, and oncology. Its portfolio of 34+ products includes the metoject/metex PEN methotrexate autoinjector (launched 2013 as the world's first MTX-filled autoinjector), BCG-medac for non-muscle invasive bladder cancer, Trecondi (Treosulfan) for HSCT conditioning therapy, and a broad cytostatic portfolio including 5-FU, bendamustine, irinotecan, doxorubicin, carboplatin, and lomustine. Products are manufactured at three European sites in Wedel, Dessau-Roßlau (Germany), and Brno (Czech Republic) with capabilities spanning pre-filled syringes, vials, cartridges, aseptic filling, terminal sterilisation, lyophilisation, and high-potent API handling down to OEL = 10 ng/m³.

The business operates on a dual model combining proprietary product sales with contract development and manufacturing (CDMO) services for third-party pharmaceutical clients. Proprietary products are sold B2B through owned subsidiaries in 14+ European markets plus Japan, supplemented by distribution partnerships (Clinigen for APAC, Hyphens for Southeast Asia) and the newly established Dubai entity serving MEA. CDMO services provide injectable manufacturing from clinical supply (1-50L) to large-scale commercial campaigns (up to 11,000L), including small molecules, biologics (mAbs, proteins, peptides, oligonucleotides), and antibody-drug conjugates. Manufacturing facilities are approved by US FDA, EU EMA, ANVISA Brazil, PMDA Japan, Health Canada, MFDS South Korea, and other major health authorities, enabling distribution across 90+ countries.

medac serves hospitals, oncology wards, rheumatology practices, urology departments, and transplant centers, engaging healthcare professionals through field sales teams, medical congress presence (EULAR, EADV, EBMT, PreS), an Investigator Initiated Trials program, and dedicated medical education. The company employs over 2,000 people globally and remains privately owned under managing directors Frank Lucaßen, Dr. Christian Matschke, and Dr. Christoph Willers, with recent expansion into the Middle East via the October 2025 Biotech Pharma acquisition.

Short descriptiontext

medac Group is a privately-held German pharmaceutical company founded in 1970 that develops, manufactures, and distributes specialty drugs in rheumatology, urology, hematology, and oncology across 90+ countries, serving hospitals and transplant centers from European manufacturing sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersWedel, Germany
HQ citystring
Wedel
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices16 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable manufacturing, rheumatology pharmaceuticals, oncology injectable drugs, CDMO injectable services, hematology pharmaceuticals
Industry2 codes
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from sales of proprietary and generic pharmaceutical products across four therapeutic areas: Rheumatology, Urology, Hematology, and Oncology. Products distributed globally to hospitals, clinics, and pharmacies.

medac-group.com
2CDMO Contract Manufacturing
TypeProfessional Services
Description

Contract development and manufacturing services for injectables for third-party pharmaceutical clients. Services include commercial solutions, clinical solutions, development, technology transfer, regulatory support, and packaging/storage.

medac-cdmo.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1medac CDMO
Description

Contract Development and Manufacturing Organization offering services from clinical supply to large-scale commercial manufacturing of injectables, including aseptic filling, lyophilisation, and high potent API handling.

medac-cdmo.com
+3 more records
Core offering1 text field

Medac Group develops, manufactures, and distributes pharmaceutical products with focus on four therapeutic areas: rheumatology, urology, hematology, and oncology. The portfolio spans 34+ sterile injectable products (including methotrexate autoinjectors, Treosulfan/Trecondi for HSCT conditioning, BCG immunotherapy for non-muscle invasive bladder cancer, and a broad range of cytostatic agents) manufactured in Germany and the Czech Republic and distributed across more than 90 countries. The company additionally operates a Contract Development and Manufacturing Organization (CDMO) segment providing injectable development, manufacturing, technology transfer, and regulatory support services to third-party pharmaceutical clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 32% of U.S. transplant centers ordering GRAFAPEX with 77% reorder rate
+2 more records
Product overview1 text field

Medac Group is a privately-owned pharmaceutical company founded in Germany in 1970, specializing in the development, manufacturing, and distribution of pharmaceutical products and diagnostics. The company's core portfolio spans four therapeutic areas: Rheumatology (including metoject/metex PEN, Leflunomide medac, Methotrexate formulations), Urology (BCG-medac), Hematology (Trecondi/Treosulfan, Hydroxyurea medac), and Oncology (including 5-FU medac, Bendamustin medac, Carmustine medac, Irinotecan medac, and numerous other cytostatic agents). The company also operates a Contract Development and Manufacturing Organization (CDMO) segment offering injectable manufacturing services including commercial bulk manufacturing, clinical supply, development, technology transfer, regulatory support, analytical capabilities, and packaging. Products are manufactured in Germany and Europe with distribution to over 90 countries worldwide.

Product and service23 records
15-FU medac
CategoryPharmaceutical product
Description

5-Fluorouracil is a pyrimidine analogue antimetabolite that disrupts cell division and metabolism by incorporating into DNA/RNA, leading to apoptosis. Used for various cancer treatments including colorectal, breast, and head/neck cancers.

2Abiraterone medac
CategoryPharmaceutical product
Description

Abiraterone acetate selectively inhibits the CYP17 enzyme required for androgen biosynthesis, reducing serum testosterone levels. Used for metastatic hormone-sensitive and castration-resistant prostate cancer.

3Arsenic trioxide medac
CategoryPharmaceutical product
Description

Arsenic trioxide induces morphological changes and DNA fragmentation characteristic of apoptosis in promyelocytic leukemia cells. Used for newly diagnosed and relapsed/refractory acute promyelocytic leukemia (APL) in combination with tretinoin or ATRA.

4BCG-medac
CategoryPharmaceutical product
Description

BCG-medac is an intravesical immunotherapy for non-muscle invasive bladder cancer (NMIBC) that triggers local immune activation to recognize and fight tumor cells. Contains 2×10^8 to 3×10^9 viable units of Bacillus Calmette-Guérin.

5Bendamustin medac
CategoryPharmaceutical product
Description

Bendamustine hydrochloride is an alkylating agent that cross-links DNA strands and impairs DNA synthesis and repair. Used for chronic lymphocytic leukemia, indolent non-Hodgkin's lymphoma, and multiple myeloma.

6Bleomedac
CategoryPharmaceutical product
Description

Bleomycin sulfate is a glycopeptide antibiotic that causes DNA strand breaks in cancer cells. Used for squamous cell carcinomas, Hodgkin's and non-Hodgkin's lymphoma, testicular carcinoma, and malignant pleural effusion.

7Bortezomib medac
CategoryPharmaceutical product
Description

Bortezomib is a reversible proteasome inhibitor that prevents ubiquitin-bound protein degradation, causing cancer cell death. Used for progressive multiple myeloma and mantle cell lymphoma as monotherapy or combination therapy.

8Capecitabine medac
CategoryPharmaceutical product
Description

Capecitabine is an orally administered prodrug of 5-fluorouracil that converts preferentially in tumor tissue. Used for adjuvant colon cancer treatment, metastatic colorectal cancer, advanced gastric cancer, and breast cancer.

9Carbomedac
CategoryPharmaceutical product
Description

Carboplatin is a platinum derivative that cross-links DNA strands through platinization, impairing transcription and replication. Used for advanced ovarian cancer and small cell lung carcinoma.

10Carmustine medac
CategoryPharmaceutical product
Description

Carmustine (BCNU) is a nitrosourea alkylating agent that crosses the blood-brain barrier. Used for brain tumors, lymphomas, gastrointestinal tumors, melanoma, and as conditioning treatment prior to hematopoietic stem cell transplantation.

11Dacarbazine medac
CategoryPharmaceutical product
Description

Dacarbazine is an alkylating agent that causes DNA strand breaks and inhibits nucleic acid and protein synthesis. Used for metastasized malignant melanoma, advanced Hodgkin's disease, and soft tissue sarcomas.

12Doxorubicin medac
CategoryPharmaceutical product
Description

Doxorubicin is a cytotoxic anthracycline antibiotic that causes DNA strand breaks through intercalation and topoisomerase II inhibition. Used for SCLC, ovarian carcinoma, bladder carcinoma, osteosarcoma, soft tissue sarcoma, Hodgkin's disease, various leukemias, and multiple myeloma.

13Gliolan
CategoryPharmaceutical product
Description

Gliolan (5-aminolevulinic acid hydrochloride/5-ALA HCl) is a prodrug used in fluorescence-guided tumor resection. Metabolized to protoporphyrin IX which emits red-violet fluorescence under blue light, enabling visualization of malignant glioma tissue during neurosurgery.

14Hydroxyurea medac
CategoryPharmaceutical product
Description

Hydroxycarbamide inhibits ribonucleotide reductase, disrupting DNA synthesis and cell division. Used for chronic myeloid leukemia, essential thrombocythaemia, and polycythaemia vera with high thromboembolic risk.

15Irinotecan medac
CategoryPharmaceutical product
Description

Irinotecan is a camptothecin derivative that inhibits topoisomerase I, causing DNA single-strand breaks. Used for advanced colorectal cancer in combination with 5-FU/folinic acid, and with cetuximab for KRAS wild-type metastatic colorectal cancer.

16Leflunomide medac
CategoryPharmaceutical product
Description

Leflunomide inhibits dihydroorotate dehydrogenase (DHODH), reducing lymphocyte proliferation and inflammation. Used as a disease-modifying antirheumatic drug (DMARD) for active rheumatoid arthritis and psoriatic arthritis.

17Levofolinic acid (Oncofolic)
CategoryPharmaceutical product
Description

Levofolinic acid is the active l-isomer of folinic acid used as an antidote for methotrexate toxicity and combined with 5-fluorouracil in colorectal cancer therapy. Bypasses DHFR blockage to provide reduced folate coenzymes.

18Lomustine medac
CategoryPharmaceutical product
Description

Lomustine is a nitrosourea that penetrates the blood-brain barrier and alkylates DNA guanine. Used for brain tumors, small cell lung cancer, Hodgkin's disease, melanoma, and as standard of care in WHO grade II-III gliomas with IDH mutation.

19Methotrexate 15 solution for injection medac
CategoryPharmaceutical product
Description

Methotrexate is a folic acid antagonist inhibiting dihydrofolate reductase, disrupting DNA synthesis. Used in low/medium doses for trophoblastic tumors, breast cancer, head/neck cancer, lymphomas, and ALL; high doses for osteosarcoma.

20Methotrexate 25 mg/ml and 100 mg/ml solution for injection
CategoryPharmaceutical product
Description

High-dose methotrexate for injection with antimetabolite and immunosuppressive effects. Used for various leukemias, lymphomas, head/neck cancer, breast cancer, choriocarcinoma, osteosarcoma, and bladder cancer. Also used intrathecally for meningeal leukemia prophylaxis/treatment.

21metoject/metex PEN
CategoryPharmaceutical product
Description

Methotrexate-filled autoinjector for subcutaneous administration. Since 2013, the worldwide first methotrexate-filled autoinjector making RA treatment easier for patients in Germany and Europe.

22Trecondi (Treosulfan)
CategoryPharmaceutical product
Description

Treosulfan is the only product approved since 2019 as conditioning therapy in combination with Fludarabine prior to allogeneic HSCT in adult and pediatric patients older than one month with malignant and non-malignant diseases. Manufactured by medac subsidiary Oncotec Pharma Production GmbH.

23medac CDMO Services
CategoryService offering
Description

Contract Development and Manufacturing Organization (CDMO) services providing tailored injectable solutions from clinical supply to large-scale commercial manufacturing. Services include commercial solutions, clinical solutions, development, technology transfer, global regulatory support, analytical capabilities and stability, and packaging and storage.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

Acquisition of Dubai-based Biotech Pharma, marking medac's establishment of its own entity (medac pharma LLC) in the Middle East, Africa, and Turkey region. The experienced Biotech Pharma team will manage and operate the new entity, combining local expertise with medac's international standards to expand impact and improve patient care in the MEA region.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-16
Description

medac and Clinigen expanded their existing cooperation with an exclusive marketing and distribution agreement for six key drugs produced by medac in oncology, hematology and immune-mediated diseases. Clinigen has exclusive rights to distribute these products in Australia, parts of Southeast Asia and China (APAC region). The partnership leverages Clinigen's established global distribution network, regional regulatory expertise, and market access strategies to accelerate patient access in these dynamic and growing markets.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-06-12
Description

Medac provided an independent educational grant to Medscape for the production and release of an on-demand symposium recording on HSCT conditioning regimens for AML/MDS. The symposium was presented at the EBMT 2025 Annual Meeting and attracted around 500 physicians onsite. Medscape organized and accredited the educational content.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partnership for one of medac's key autoimmune products in Southeast Asia markets. This partnership complements the broader Clinigen agreement for the APAC region.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Jordan-headquartered specialty and injectable generics pharmaceutical company with comparable portfolio in oncology injectables and hospital-focused specialty products. Both operate CDMO-adjacent injectable manufacturing capabilities and compete in similar hospital procurement channels across Europe and MEA.

TypeDirect peer
Description

German-headquartered specialty and generics pharmaceutical company with a similar product portfolio across multiple therapeutic areas and strong European manufacturing footprint. Both companies target the same hospital and specialty pharmacy channels with mature molecules in oncology, rheumatology, and adjacent indications.

3Recipharm
TypeDirect peer
Description

European-headquartered CDMO offering sterile injectable manufacturing, fill-finish services, and pharmaceutical development across multiple dosage forms. Directly comparable to medac's CDMO division serving third-party pharma clients with injectable contract manufacturing.

TypeDirect peer
Description

South African-headquartered specialty and generics pharmaceutical group with significant oncology and injectable manufacturing operations. Comparable focus on hospital-channel specialty generics across emerging markets including MEA, where medac recently entered via Biotech Pharma acquisition.

TypeBroad incumbent
Description

Indian-headquartered global pharmaceutical manufacturer with extensive generic injectables and oncology portfolio. Competes with medac in hospital-channel generics across Europe and global markets, often on price-led positioning.

TypeBroad incumbent
Description

Global pharmaceutical company with one of the largest specialty and generics portfolios including oncology and injectable products. Overlaps with medac on multiple generic molecules while operating at significantly larger scale across global markets.

TypeDirect peer
Description

Spanish specialty pharmaceutical company with dermatology and rheumatology focus and European commercial footprint. Comparable business model targeting specialty prescribers with branded formulations of mature molecules across European markets.

TypeDirect peer
Description

German-headquartered CDMO with capabilities in sterile injectables, solid dosage forms, and contract development services for pharmaceutical clients. Closely comparable to medac CDMO on injectable contract manufacturing services in the European market.

9Sandoz (Novartis)
TypeBroad incumbent
Description

Global generics and biosimilars leader spun out from Novartis, with broad portfolio including oncology injectables and hospital specialty generics. Much larger scale than medac but competes directly on the same oncology generic molecules across global markets.

TypeDirect peer
Description

Italian specialty pharmaceutical company with established presence in oncology, rheumatology, and rare disease therapeutic areas across Europe and global markets. Similar business model combining proprietary specialty products with manufacturing scale in Europe.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medac Group

Specialty Pharmaceuticalsmedac-group.com

medac Group is a privately-held German pharmaceutical company founded in 1970 that develops, manufactures, and distributes specialty drugs in rheumatology, urology, hematology, and oncology across 90+ countries, serving hospitals and transplant centers from European manufacturing sites.

What Medac Group does

medac Group is a privately-held German pharmaceutical company founded in 1970 and headquartered in Wedel, near Hamburg. The company develops, manufactures, and distributes specialty pharmaceutical products across four therapeutic areas: rheumatology, urology, hematology, and oncology. Its portfolio of 34+ products includes the metoject/metex PEN methotrexate autoinjector (launched 2013 as the world's first MTX-filled autoinjector), BCG-medac for non-muscle invasive bladder cancer, Trecondi (Treosulfan) for HSCT conditioning therapy, and a broad cytostatic portfolio including 5-FU, bendamustine, irinotecan, doxorubicin, carboplatin, and lomustine. Products are manufactured at three European sites in Wedel, Dessau-Roßlau (Germany), and Brno (Czech Republic) with capabilities spanning pre-filled syringes, vials, cartridges, aseptic filling, terminal sterilisation, lyophilisation, and high-potent API handling down to OEL = 10 ng/m³.

The business operates on a dual model combining proprietary product sales with contract development and manufacturing (CDMO) services for third-party pharmaceutical clients. Proprietary products are sold B2B through owned subsidiaries in 14+ European markets plus Japan, supplemented by distribution partnerships (Clinigen for APAC, Hyphens for Southeast Asia) and the newly established Dubai entity serving MEA. CDMO services provide injectable manufacturing from clinical supply (1-50L) to large-scale commercial campaigns (up to 11,000L), including small molecules, biologics (mAbs, proteins, peptides, oligonucleotides), and antibody-drug conjugates. Manufacturing facilities are approved by US FDA, EU EMA, ANVISA Brazil, PMDA Japan, Health Canada, MFDS South Korea, and other major health authorities, enabling distribution across 90+ countries.

medac serves hospitals, oncology wards, rheumatology practices, urology departments, and transplant centers, engaging healthcare professionals through field sales teams, medical congress presence (EULAR, EADV, EBMT, PreS), an Investigator Initiated Trials program, and dedicated medical education. The company employs over 2,000 people globally and remains privately owned under managing directors Frank Lucaßen, Dr. Christian Matschke, and Dr. Christoph Willers, with recent expansion into the Middle East via the October 2025 Biotech Pharma acquisition.

Medac Group firmographics

Firmographics
Name
Medac Group
Legal name
medac Gesellschaft für klinische Spezialpräparate m.b.H.
Website
https://medac-group.com
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
medac Group is a privately-held German pharmaceutical company founded in 1970 that develops, manufactures, and distributes specialty drugs in rheumatology, urology, hematology, and oncology across 90+ countries, serving hospitals and transplant centers from European manufacturing sites.
Ownership category
akta.pro rank

Medac Group industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Sterile injectable manufacturing
  • Rheumatology pharmaceuticals
  • Oncology injectable drugs
  • CDMO injectable services
  • Hematology pharmaceuticals

Where Medac Group is headquartered

Location

Headquarters

HQ city
Wedel
HQ country
Germany
HQ region
Europe

Offices16 records

Markets served

Medac Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Revenue from sales of proprietary and generic pharmaceutical products across four therapeutic areas: Rheumatology, Urology, Hematology, and Oncology. Products distributed globally to hospitals, clinics, and pharmacies.
  2. CDMO Contract Manufacturing: Contract development and manufacturing services for injectables for third-party pharmaceutical clients. Services include commercial solutions, clinical solutions, development, technology transfer, regulatory support, and packaging/storage.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Medac Group product offering

Product offering

Core offering

Medac Group develops, manufactures, and distributes pharmaceutical products with focus on four therapeutic areas: rheumatology, urology, hematology, and oncology. The portfolio spans 34+ sterile injectable products (including methotrexate autoinjectors, Treosulfan/Trecondi for HSCT conditioning, BCG immunotherapy for non-muscle invasive bladder cancer, and a broad range of cytostatic agents) manufactured in Germany and the Czech Republic and distributed across more than 90 countries. The company additionally operates a Contract Development and Manufacturing Organization (CDMO) segment providing injectable development, manufacturing, technology transfer, and regulatory support services to third-party pharmaceutical clients.

Product overview

Medac Group is a privately-owned pharmaceutical company founded in Germany in 1970, specializing in the development, manufacturing, and distribution of pharmaceutical products and diagnostics. The company's core portfolio spans four therapeutic areas: Rheumatology (including metoject/metex PEN, Leflunomide medac, Methotrexate formulations), Urology (BCG-medac), Hematology (Trecondi/Treosulfan, Hydroxyurea medac), and Oncology (including 5-FU medac, Bendamustin medac, Carmustine medac, Irinotecan medac, and numerous other cytostatic agents). The company also operates a Contract Development and Manufacturing Organization (CDMO) segment offering injectable manufacturing services including commercial bulk manufacturing, clinical supply, development, technology transfer, regulatory support, analytical capabilities, and packaging. Products are manufactured in Germany and Europe with distribution to over 90 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • medac CDMO: Contract Development and Manufacturing Organization offering services from clinical supply to large-scale commercial manufacturing of injectables, including aseptic filling, lyophilisation, and high potent API handling.
  • metoject/metex PEN
  • BCG-medac
  • Trecondi

Products and services

  • 5-FU medac 5-Fluorouracil is a pyrimidine analogue antimetabolite that disrupts cell division and metabolism by incorporating into DNA/RNA, leading to apoptosis. Used for various cancer treatments including colorectal, breast, and head/neck cancers.
  • Abiraterone medac Abiraterone acetate selectively inhibits the CYP17 enzyme required for androgen biosynthesis, reducing serum testosterone levels. Used for metastatic hormone-sensitive and castration-resistant prostate cancer.
  • Arsenic trioxide medac Arsenic trioxide induces morphological changes and DNA fragmentation characteristic of apoptosis in promyelocytic leukemia cells. Used for newly diagnosed and relapsed/refractory acute promyelocytic leukemia (APL) in combination with tretinoin or ATRA.
  • BCG-medac BCG-medac is an intravesical immunotherapy for non-muscle invasive bladder cancer (NMIBC) that triggers local immune activation to recognize and fight tumor cells. Contains 2×10^8 to 3×10^9 viable units of Bacillus Calmette-Guérin.
  • Bendamustin medac Bendamustine hydrochloride is an alkylating agent that cross-links DNA strands and impairs DNA synthesis and repair. Used for chronic lymphocytic leukemia, indolent non-Hodgkin's lymphoma, and multiple myeloma.
  • Bleomedac Bleomycin sulfate is a glycopeptide antibiotic that causes DNA strand breaks in cancer cells. Used for squamous cell carcinomas, Hodgkin's and non-Hodgkin's lymphoma, testicular carcinoma, and malignant pleural effusion.
  • Bortezomib medac Bortezomib is a reversible proteasome inhibitor that prevents ubiquitin-bound protein degradation, causing cancer cell death. Used for progressive multiple myeloma and mantle cell lymphoma as monotherapy or combination therapy.
  • Capecitabine medac Capecitabine is an orally administered prodrug of 5-fluorouracil that converts preferentially in tumor tissue. Used for adjuvant colon cancer treatment, metastatic colorectal cancer, advanced gastric cancer, and breast cancer.
  • Carbomedac Carboplatin is a platinum derivative that cross-links DNA strands through platinization, impairing transcription and replication. Used for advanced ovarian cancer and small cell lung carcinoma.
  • Carmustine medac Carmustine (BCNU) is a nitrosourea alkylating agent that crosses the blood-brain barrier. Used for brain tumors, lymphomas, gastrointestinal tumors, melanoma, and as conditioning treatment prior to hematopoietic stem cell transplantation.
  • Dacarbazine medac Dacarbazine is an alkylating agent that causes DNA strand breaks and inhibits nucleic acid and protein synthesis. Used for metastasized malignant melanoma, advanced Hodgkin's disease, and soft tissue sarcomas.
  • Doxorubicin medac Doxorubicin is a cytotoxic anthracycline antibiotic that causes DNA strand breaks through intercalation and topoisomerase II inhibition. Used for SCLC, ovarian carcinoma, bladder carcinoma, osteosarcoma, soft tissue sarcoma, Hodgkin's disease, various leukemias, and multiple myeloma.
  • Gliolan Gliolan (5-aminolevulinic acid hydrochloride/5-ALA HCl) is a prodrug used in fluorescence-guided tumor resection. Metabolized to protoporphyrin IX which emits red-violet fluorescence under blue light, enabling visualization of malignant glioma tissue during neurosurgery.
  • Hydroxyurea medac Hydroxycarbamide inhibits ribonucleotide reductase, disrupting DNA synthesis and cell division. Used for chronic myeloid leukemia, essential thrombocythaemia, and polycythaemia vera with high thromboembolic risk.
  • Irinotecan medac Irinotecan is a camptothecin derivative that inhibits topoisomerase I, causing DNA single-strand breaks. Used for advanced colorectal cancer in combination with 5-FU/folinic acid, and with cetuximab for KRAS wild-type metastatic colorectal cancer.
  • Leflunomide medac Leflunomide inhibits dihydroorotate dehydrogenase (DHODH), reducing lymphocyte proliferation and inflammation. Used as a disease-modifying antirheumatic drug (DMARD) for active rheumatoid arthritis and psoriatic arthritis.
  • Levofolinic acid (Oncofolic) Levofolinic acid is the active l-isomer of folinic acid used as an antidote for methotrexate toxicity and combined with 5-fluorouracil in colorectal cancer therapy. Bypasses DHFR blockage to provide reduced folate coenzymes.
  • Lomustine medac Lomustine is a nitrosourea that penetrates the blood-brain barrier and alkylates DNA guanine. Used for brain tumors, small cell lung cancer, Hodgkin's disease, melanoma, and as standard of care in WHO grade II-III gliomas with IDH mutation.
  • Methotrexate 15 solution for injection medac Methotrexate is a folic acid antagonist inhibiting dihydrofolate reductase, disrupting DNA synthesis. Used in low/medium doses for trophoblastic tumors, breast cancer, head/neck cancer, lymphomas, and ALL; high doses for osteosarcoma.
  • Methotrexate 25 mg/ml and 100 mg/ml solution for injection High-dose methotrexate for injection with antimetabolite and immunosuppressive effects. Used for various leukemias, lymphomas, head/neck cancer, breast cancer, choriocarcinoma, osteosarcoma, and bladder cancer. Also used intrathecally for meningeal leukemia prophylaxis/treatment.
  • metoject/metex PEN Methotrexate-filled autoinjector for subcutaneous administration. Since 2013, the worldwide first methotrexate-filled autoinjector making RA treatment easier for patients in Germany and Europe.
  • Trecondi (Treosulfan) Treosulfan is the only product approved since 2019 as conditioning therapy in combination with Fludarabine prior to allogeneic HSCT in adult and pediatric patients older than one month with malignant and non-malignant diseases. Manufactured by medac subsidiary Oncotec Pharma Production GmbH.
  • medac CDMO Services Contract Development and Manufacturing Organization (CDMO) services providing tailored injectable solutions from clinical supply to large-scale commercial manufacturing. Services include commercial solutions, clinical solutions, development, technology transfer, global regulatory support, analytical capabilities and stability, and packaging and storage.

Quantifiable outcome

  • 32% of U.S. transplant centers ordering GRAFAPEX with 77% reorder rate
  • +2 more outcomes

Companies that use Medac Group

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles2 records

Medac Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Medac Group partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Biotech PharmacoreStrategic or Co-development Partner · 14 October 2025Acquisition of Dubai-based Biotech Pharma, marking medac's establishment of its own entity (medac pharma LLC) in the Middle East, Africa, and Turkey region. The experienced Biotech Pharma team will manage and operate the new entity, combining local expertise with medac's international standards to expand impact and improve patient care in the MEA region.
  • Clinigen GroupcoreChannel Partner/ Reseller/ Distributor · 16 June 2025medac and Clinigen expanded their existing cooperation with an exclusive marketing and distribution agreement for six key drugs produced by medac in oncology, hematology and immune-mediated diseases. Clinigen has exclusive rights to distribute these products in Australia, parts of Southeast Asia and China (APAC region). The partnership leverages Clinigen's established global distribution network, regional regulatory expertise, and market access strategies to accelerate patient access in these dynamic and growing markets.
  • MedscapeminorGTM or Marketing Partner · 12 June 2025Medac provided an independent educational grant to Medscape for the production and release of an on-demand symposium recording on HSCT conditioning regimens for AML/MDS. The symposium was presented at the EBMT 2025 Annual Meeting and attracted around 500 physicians onsite. Medscape organized and accredited the educational content.
  • Hyphens PharmaminorChannel Partner/ Reseller/ DistributorDistribution partnership for one of medac's key autoimmune products in Southeast Asia markets. This partnership complements the broader Clinigen agreement for the APAC region.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Medac Group competitors and assessment

Company assessment

Direct peers

  • Hikma Pharmaceuticals: Jordan-headquartered specialty and injectable generics pharmaceutical company with comparable portfolio in oncology injectables and hospital-focused specialty products. Both operate CDMO-adjacent injectable manufacturing capabilities and compete in similar hospital procurement channels across Europe and MEA.
  • Stada Arzneimittel: German-headquartered specialty and generics pharmaceutical company with a similar product portfolio across multiple therapeutic areas and strong European manufacturing footprint. Both companies target the same hospital and specialty pharmacy channels with mature molecules in oncology, rheumatology, and adjacent indications.
  • Recipharm: European-headquartered CDMO offering sterile injectable manufacturing, fill-finish services, and pharmaceutical development across multiple dosage forms. Directly comparable to medac's CDMO division serving third-party pharma clients with injectable contract manufacturing.
  • Aspen Pharmacare: South African-headquartered specialty and generics pharmaceutical group with significant oncology and injectable manufacturing operations. Comparable focus on hospital-channel specialty generics across emerging markets including MEA, where medac recently entered via Biotech Pharma acquisition.
  • Almirall: Spanish specialty pharmaceutical company with dermatology and rheumatology focus and European commercial footprint. Comparable business model targeting specialty prescribers with branded formulations of mature molecules across European markets.
  • Aenova Group: German-headquartered CDMO with capabilities in sterile injectables, solid dosage forms, and contract development services for pharmaceutical clients. Closely comparable to medac CDMO on injectable contract manufacturing services in the European market.
  • Recordati: Italian specialty pharmaceutical company with established presence in oncology, rheumatology, and rare disease therapeutic areas across Europe and global markets. Similar business model combining proprietary specialty products with manufacturing scale in Europe.

Broad incumbents

  • Aurobindo Pharma: Indian-headquartered global pharmaceutical manufacturer with extensive generic injectables and oncology portfolio. Competes with medac in hospital-channel generics across Europe and global markets, often on price-led positioning.
  • Teva Pharmaceutical Industries: Global pharmaceutical company with one of the largest specialty and generics portfolios including oncology and injectable products. Overlaps with medac on multiple generic molecules while operating at significantly larger scale across global markets.
  • Sandoz (Novartis): Global generics and biosimilars leader spun out from Novartis, with broad portfolio including oncology injectables and hospital specialty generics. Much larger scale than medac but competes directly on the same oncology generic molecules across global markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Medac Group social profiles

Digital presence

Medac Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medac Group leadership team

Management profile

Number of profiles

Profiles10 records

Medac Group subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Medac Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medac Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medac Group

What does Medac Group do?

Medac Group develops, manufactures, and distributes pharmaceutical products with focus on four therapeutic areas: rheumatology, urology, hematology, and oncology. The portfolio spans 34+ sterile injectable products (including methotrexate autoinjectors, Treosulfan/Trecondi for HSCT conditioning, BCG immunotherapy for non-muscle invasive bladder cancer, and a broad range of cytostatic agents) manufactured in Germany and the Czech Republic and distributed across more than 90 countries. The company additionally operates a Contract Development and Manufacturing Organization (CDMO) segment providing injectable development, manufacturing, technology transfer, and regulatory support services to third-party pharmaceutical clients.

Is Medac Group a public or private company?

Medac Group is a private company. It is classified as family owned and is currently operating.

When was Medac Group founded?

Medac Group was founded in 1970. It employs 1,001 to 5,000 people.

Where is Medac Group based?

Medac Group is headquartered in Wedel, Germany, in the Europe region.

How does Medac Group make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are CDMO Contract Manufacturing.

Who are Medac Group's main competitors?

Direct peers on record are Hikma Pharmaceuticals, Stada Arzneimittel, Recipharm, Aspen Pharmacare, Almirall, Aenova Group and Recordati. Broad incumbents are Aurobindo Pharma, Teva Pharmaceutical Industries and Sandoz (Novartis).

Does Medac Group have an API?

No public API is recorded for Medac Group.

What industry is Medac Group in?

Medac Group's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic), with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals